Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries

In this clinical trial adult patients diagnosed with follicular lymphoma and relapse or progression of disease within 24 months of starting first line treatment will be treated with mosunetuzumab. This is a bispecific antibody, a new type of immunotherapy that redirects the bodies own immune cells (T-cells) to attack and kill the lymphoma cells. The main question the trial aims to answer is if mosunetuzumab works better than standard treatments in this sub-group of patients. Patients will receive mosunetuzumab as injections in the abdominal subcutaneous fat once a week for the three first dose

Trial Details

NCT ID
NCT05849857
Phase
PHASE2
Sponsor
Oslo University Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Mosunetuzumab
Locations (sample)
  • Helsinki, Finland|60.16952,24.93545
  • Oslo, Norway|59.91273,10.74609
  • Trondheim, Norway|63.43049,10.39506

Key Eligibility Criteria

  • Written informed consent according to ICH-GCP guidelines.
  • Age ≥ 18 years.
  • Follicular lymphoma grade 1-3a with a current relapse or progression within 24 months of starting 1st line treatment or refractory to 1st line trea…
  • Documented current relapse or progression of FL within 24 months of starting first line treatment containing a monospecific anti-CD20 antibody (suc…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →